MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering Pharma
Advertisement
MorphoSys AG announced that Bayer Schering Pharma AG, Germany has filed all necessary documentation to initiate a Phase 1 clinical trial with a HuCAL-derived antibody-drug conjugate (ADC) in the therapeutic area of oncology. This achievement marks a significant milestone within the Bayer Schering Pharma alliance and triggers a payment to MorphoSys.
The current program is directed against the target molecule MN, also known as Carbonic Anhydrase or CA IX for short, a tumor associated antigen expressed in many tumor types under hypoxic conditions. The antibody is the first fully human HuCAL-based ADC to enter clinical trials. ADCs comprise antibodies linked to cytotoxic drugs, and combine the targeting properties of the antibody with the cell-destroying effect of the conjugated drug. In the present program, the HuCAL-derived antibody-drug conjugate incorporates technology licensed to Bayer Schering Pharma from Seattle Genetics.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
OncoMethylome shareholders pass all resolutions at AGM and appoint three new independent directors
Medicago succesfully expresses VLP antigen for A H1N1 strain
ADC Therapeutics Appoints Dr. Chris Martin as Chief Executive Officer
Merck Boosts Commercial Capacity in France - Merck has opened a commercial facility for its new Millipore® CTDMO Services offering at the company’s site in Martillac, France
"Make two out of one" - Division of Artificial Cells - Scientists uncover a novel and generic mechanism for the division of artificial cells into two daughter cells
Avilex Pharma receives Wellcome Trust Translation Award
NetScientific appoints Dr François R. Martelet as Chief Executive Officer
Dendreon Announces Strategic Realignment to Focus on PROVENGE BLA and Commercialization
